Day One Biopharmaceuticals, Inc. (DAWN) Q3 2021 Earnings Results

Day One Biopharma Misses on EPS — Stock Down 5.7%

The earnings report indicates that Day One Biopharma is still in the early stages of its development, as reflected by the lack of revenue and a loss per share. The stock fell 5.7% following the announcement, likely due to the missed EPS and the absence of guidance, which may leave investors uncertain about the company's near-term outlook.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.33	N/A	-17.86%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed a commitment to their clinical pipeline but did not offer any forward-looking guidance. The tone was cautious regarding future expectations.

Management did not provide specific guidance for future performance.

The company is focused on advancing its clinical programs.

Day One Biopharma Misses on EPS — Stock Down 5.7%

Key numbers

Management commentary

Day One Biopharmaceuticals, Inc.

More earnings this week

Day One Biopharma Misses on EPS — Stock Down 5.7%

Key numbers

Management commentary